Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from 68Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient.

Abstract

BACKGROUND:

Neuroendocrine tumors (NETs) frequently overexpress somatostatin receptors (SSTRs), which is the molecular basis for 68Ga-DOTATOC positron-emission tomography (PET) and radiopeptide therapy (PRRT). However, SSTR expression fluctuates and can be subject to treatment-related changes. The aim of this retrospective study was to assess, which changes in PET and apparent diffusion coefficient (ADC) occur for different treatments and if pre-therapeutic 68Ga-DOTATOC-PET/MRI was able to predict treatment response to PRRT.

METHODS:

Patients with histopathologically confirmed NET, at least one liver metastasis > 1 cm and at least two 68Ga-DOTATOC-PET/MRI including ADC maps were eligible. 68Ga-DOTATOC-PET/MRI of up to 5 liver lesions per patients was subsequently analyzed. Extracted features comprise conventional PET parameters, such as maximum and mean standardized uptake value (SUVmax and SUVmean) and ADC values. Furthermore, textural features (TFs) from both modalities were extracted. In patients with multiple 68Ga-DOTATOC-PET/MRI a pair of 2 scans each was analyzed separately and the parameter changes between both scans calculated. The same image analysis was performed in patients with 68Ga-DOTATOC-PET/MRI before PRRT. Differences in PET and ADC maps parameters between PRRT-responders and non-responders were compared using Mann-Whitney test to test differences among groups for statistical significance.

RESULTS:

29 pairs of 68Ga-DOTATOC-PET/MRI scans of 18 patients were eligible for the assessment of treatment-related changes. In 12 cases patients were treated with somatostatin analogues between scans, in 9 cases with PRRT and in 2 cases each patients received local treatment, chemotherapy and sunitinib. Treatment responders showed a statistically significant decrease in lesion volume and a borderline significant decrease in entropy on ADC maps when compared to non-responders. Patients treated with standalone SSA showed a borderline significant decrease in mean and maximum ADC, compared to patients treated with PRRT. No parameters were able to predict treatment response to PRRT on pre-therapeutic 68Ga-DOTATOC-PET/MRI.

CONCLUSIONS:

Patients responding to current treatment showed a statistically significant decrease in lesion volume on ADC maps and a borderline significant decrease in entropy. No statistically significant changes in PET parameters were observed. No PET or ADC maps parameters predicted treatment response to PRRT. However, the sample size of this preliminary study is small and further research needed.

• Authors: Manuel Weber, Lukas Kessler, Benedikt Schaarschmidt, Wolfgang Peter Fendler, Harald Lahner, Gerald Antoch, Lale Umutlu, Ken Herrmann, Christoph Rischpler
• Journal: BMC cancer (BMC Cancer) Vol. 20 Issue 1 Pg. 326 (Apr 16 2020) ISSN: 1471-2407 [Electronic] England
• PMID: 32299391 (Publication Type: Journal Article)

Chemical References

• Gallium Radioisotopes
• Radiopharmaceuticals
• Receptors, Somatostatin

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Diffusion Magnetic Resonance Imaging (methods)
• Female
• Follow-Up Studies
• Gallium Radioisotopes (metabolism)
• Humans
• Liver Neoplasms (diagnostic imaging, drug therapy, metabolism, pathology)
• Male
• Middle Aged
• Multimodal Imaging (methods)
• Neuroendocrine Tumors (diagnostic imaging, drug therapy, metabolism, pathology)
• Positron-Emission Tomography (methods)
• Prognosis
• Radiopharmaceuticals (metabolism)
• Receptors, Somatostatin (metabolism)
• Retrospective Studies
• Young Adult